Syngeneic

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic and semiallogeneic system. ❋ Unknown (1996)

To investigate whether MSCs could provide a neuroprotective effect, we isolated and injected intravenously syngeneic MSCs into RCS rats at P30 (n = 12), at which time the retinal degeneration is at an early stage. ❋ Shaomei Wang Et Al. (2010)

Moreover, this treatment enables the T-cell-induced reduction of tumor growth in syngeneic immunocompetent mice and enhanced levels of B16F10 specific CD8 T lymphocytes TRP-2/H-2K ❋ Guillaume Sarrabayrouse Et Al. (2010)

Vaccination of syngeneic mice with mIFN-γ+GGTI-298 pretreated B16F10 cells induces resistance to untreated tumor growth. ❋ Guillaume Sarrabayrouse Et Al. (2010)

Animals received syngeneic MSCs (1×106 cells) by tail vein at an age before major photoreceptor loss. ❋ Shaomei Wang Et Al. (2010)

Again syngeneic mice were vaccinated as previously described and challenged intra-venously with 5×10 ❋ Guillaume Sarrabayrouse Et Al. (2010)

Indeed, in vivo vaccination of syngeneic mice with pharmacologically pretreated melanoma cells induces tumor growth slowing down and reduction of pulmonary metastases implantation. ❋ Guillaume Sarrabayrouse Et Al. (2010)

To test whether pharmacological treatment of melanoma cells with IFN-γ and GGTI-298 could produce suitable cells for vaccination a murine model was used: B16F10 cell line, a poorly immunogenic and MHC-I negative melanoma of spontaneous origin, was injected in the syngeneic C57Bl/6 mice. ❋ Guillaume Sarrabayrouse Et Al. (2010)

EOMA cells are tumorigenic in syngeneic mice and exhibit characteristic endothelial cell properties.

Additionally, XMT-1107 was active in a number of syngeneic and xenograft tumor models.

Taylor CC, Sweetwood JP, Cheng Y, Pace JL, et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. ❋ Unknown (2009)

Utilizing syngeneic brain tumor models we demonstrate that it is possible to stimulate a systemic antitumor immune response by modifying the brain tumor microenvironment through the recruitment of DCs to the tumor milieu in combination with tumor cell killing. ❋ Unknown (2009)

(F) A syngeneic MLR was used to determine if TLR2 activation on DCs can induce tumor antigen specific T cell proliferation. ❋ Unknown (2009)

Pbγ-spz-immunized-challenged mice and from naïve-challenged mice and adoptively transferred into naïve syngeneic recipients (n = 13) that were challenged 7 days later with either 250 (n = 6) or 1000 (n = 7) infectious sporozoites. ❋ Unknown (2009)